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Disease-causing missense mutations in NPHS2 gene alter nor-
mal nephrin trafficking to the plasma membrane.
Background. Podocin is a membrane-integrated protein that
is located at the glomerular slit diaphragm and directly interacts
with nephrin. The gene encoding podocin, NPHS2, is mutated
in patients with autosomal-recessive steroid-resistant nephrotic
syndrome (SRN). In order to study a potential pathomechanism
of massive proteinuria in patients with SRN, we have investi-
gated the trafficking and subcellular localization of five common
disease-causing missense mutants of human podocin.
Methods. Site-directed mutagenesis was applied to generate
cDNA constructs encoding five different missense mutations of
human podocin (P20L, G92C, R138Q, V180M, and R291W).
To identify the subcellular localization of each mutant in trans-
fected human embryonic kidney (HEK)293 cells, we have gen-
erated and characterized a rabbit polyclonal antibody against
the human podocin. Specificity of the antibody was determined
by light and immunoelectron microscopy, as well as immunoblot
analysis using human glomeruli. Confocal microscopy was ap-
plied to determine subcellular localization of the wild-type and
the mutated podocin molecules, as well as wild-type nephrin
in transfected cells. Immunoprecipitation and pull-down stud-
ies were carried out to investigate the molecular interaction of
podocin mutants and wild-type nephrin.
Results. Immunofluorescence and confocal microscopy
showed that wild-type podocin located to the plasma membrane
when expressed in HEK293 cells. Two missense mutations, P20L
and G92C, located at the N-terminus part of the molecule, were
also present at the plasma membrane, indicating that these mu-
tations did not affect the subcellular localization of the mutated
podocin molecules. In contrast, subcellular localization of three
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other missense mutants located in the proximal C-terminus part
of the protein was drastically altered, in which R138Q was re-
tained in the endoplasmic reticulum (ER), V180M formed in-
clusion bodies in the cytoplasm, and the R291W mutant was
trapped both in the ER and in small intracellular vesicles. Inter-
estingly, this abnormal subcellular localization of podocin mis-
sense mutants also resulted in alteration in protein trafficking
of wild-type nephrin in cotransfected cells through the strong
protein binding between both molecules.
Conclusion. In patients with SRN, some missense mutations
in the NPHS2 gene not only lead to misfolding and mislocal-
ization of the mutated podocin, but they can also interfere with
slit diaphragm structure and function by altering the proper
trafficking of nephrin to the plasma membrane.
Pathomechanism of the proteinuria in congenital and
acquired forms of glomerular diseases are diverse and
dependent on different underlying factors. Characteri-
zation of the recently identified gene NPHS1 [1], mu-
tated in the congenital nephrotic syndrome of the Finnish
type (CNF), has shed much light onto the pathomecha-
nism of nephrotic syndromes. The discovery of the gene
and localization of its product has dramatically increased
our understanding of the nature of the glomerular ul-
trafiltration barrier. The gene product, termed nephrin,
is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily molecules [2]. Nephrin is
currently thought to be a major component of the slit
diaphragm (SD) structure, which connects the interdigi-
tating foot processes of the glomerular podocytes [3–5].
In the past few years, intensive research focused on
the molecular basis of the SD structure and function
has resulted in identification of several novel SD-
associated proteins such as NEPH1, CD2-associated pro-
tein (CD2AP), and podocin. NEPH1, similar to nephrin,
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is also a member of the immunoglobulin superfamily with
five extracellular Ig-like domains and a cytoplasmic do-
main [6]. It has recently been shown that NEPH1 can
form heterodimer with nephrin at its extracellular do-
main [7]. CD2AP is an 80-kD protein that was originally
found to be associated with the cytoplasmic domain of
CD2, a transmembrane protein also belonging to the
immunoglobulin superfamily, expressed on T cells and
natural killer cells [8]. Subsequent work by Shaw et al
clearly demonstrated that this protein was also expressed
by podocytes and localized at the glomerular SD area
connecting the cytoplasmic domain of nephrin with the
actin cytoskeleton [9, 10]; however, nephrotic syndrome
with a mutated CD2AP gene has not yet been identi-
fied. On the other hand, NPHS2, mutated in patients
with autosomal-recessive steroid-resistant nephrotic syn-
drome (SRN), has been recently identified [11]. The prod-
uct of this gene, termed podocin, is a membrane-integral
protein belonging to the stomatin family. In the kidney, it
is exclusively localized at the cytoplasmic face of the SD
[12]. Pull-down studies have shown that podocin inter-
acts with the cytoplasmic part of nephrin, thus being an
important component of the glomerular filtration barrier
[13].
SRN is a specific type of familial steroid-resistant
idiopathic nephrotic syndrome characterized by an
autosomal-recessive inheritance, with onset between
three months to five years. The massive proteinuria in
these patients does not respond to glucocorticoid treat-
ment, resulting in rapid progression to end-stage renal
disease. The histologic findings are quite interesting in
that minimal glomerular legions are seen at early stages,
followed by focal segmental glomerulosclerosis (FSGS)
at later stage. It was originally reported that many non-
sense, insertion, deletion, and missense mutations are re-
sponsible for SRN [11]. However, rapidly accumulated
reports have clarified broad implication of these podocin
mutations, not only in the pathophysiology of children
with SRN, but also in the cases with nonfamilial FSGS
[14, 15], glucocorticoid-sensitive frequent relapses [16],
and with sporadic FSGS in adulthood [17]. These results
point to the central role of podocin together with nephrin
for a functional permselectivity of the SD.
Recently, we have reported that the majority of mis-
sense mutated nephrin are retained in the endoplasmic
reticulum (ER), and do not appear on the plasma mem-
brane [18]. In the present study, we have explored a
potential pathomechanism in development of steroid-
resistant nephrotic syndrome in patients with missense
podocin mutations. We have generated cDNA constructs
with five different disease-causing missense mutations
commonly found in SRN patients and analyzed the
subcellular localization of these mutants in human em-
bryonic kidney cells (HEK293). Three out of these five
mutations, located at the proximal C-terminal part of
podocin molecule, failed to localize to the plasma mem-
brane. Interestingly, we also found that the normal lo-
calization of wild-type nephrin at the plasma membrane
was also altered in cells coexpressing these three podocin
mutants. Our findings point to a potential pathomecha-
nism in massive proteinuria in some patients with SRN,
in which the proper slit diaphragm localization of both
podocin and nephrin molecules are disrupted.
METHODS
Antibodies
Antihuman podocin polyclonal antibody (KYJ2) was
generated against a synthetic peptide corresponding to
KRAKAERSGGGRGRQE (amino acids 25–40) of the
human podocin amino acid sequence. A rabbit was im-
munized with 0.5 mg of this peptide conjugated to the
carrier protein keyhole limpet hemocyanin, and boosted
three times with 0.5 mg of the immunogen each time.
The rabbit was sacrificed and bled 10 days after the
last immunization. The antiserum was affinity-purified
with the corresponding peptide linked to CNBr-activated
Sepharose 4B column (Pharmacia, Piscataway, NJ, USA).
Horseradish peroxidase (HRP)–labeled anti-podocin an-
tibody was generated according to the procedure of
Wilson and Nakane [19], with minor modifications.
Mouse monoclonal antibody raised against the eighth Ig
domain (mAb2) and rabbit polyclonal antibody against
the whole intracellular domain (pAb2) of nephrin, as
described before [20], and mouse monoclonal antibody
against human podocalyxin (3D3) [21] were used for
immunofluorescence study or immunoblotting. The fol-
lowing antibodies were purchased from the suppliers
as indicated: monoclonal anti-GM130 antibody (Becton
Dickinson Transduction Laboratories, Franklin Lakes,
NJ, USA); monoclonal anti- KDEL (GRP78/94) anti-
body (Stressgen, Victoria, British Columbia, Canada),
HRP-labeled goat antirabbit immunoglobulins (Dako;
Carpinteria, CA, USA); Alexa Fluor 488-conjugated goat
antimouse IgG and antirabbit IgG, and Texas Red-X goat
antimouse IgG (Molecular Probes, Eugene, OR, USA),
colloidal gold (12 and 18 nm)-labeled donkey antirab-
bit IgG (Jackson Immunoresearch Laboratories, West
Grove, PA, USA).
Normal kidney samples and isolation of glomeruli
Four human kidney cortex samples were obtained
from histologically normal regions of fresh kidneys from
patients undergoing nephrectomy with renal cancer or
ureter cancer at the Department of Urology, Kyorin Uni-
versity Hospital. Informed consent was obtained from all
patients. The isolation of glomeruli was performed by a
differential sieving technique as described previously [22,
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23]. The purity of the glomerular preparations, as assessed
by phase-contrast microscopy, was above 95%.
Immunoperoxidase staining
Immunoperoxidase staining was performed using
frozen kidney cortex samples [22, 23]. Briefly, the slides
were washed with phosphate-buffered saline (PBS) and
incubated with 1% H2O2/PBS for 30 minutes to quench
endogenous peroxidase activity. After washing with PBS,
the slides were incubated with blocking buffer (2%
bovine serum albumin, 5% goat serum, and 0.05%
Tween-20 in PBS), and then reacted for 60 minutes at
room temperature with KYJ2 antiserum or preimmune
rabbit serum (1:500). After washing with PBS, the slides
were incubated at room temperature with HRP-labeled
goat antirabbit antibody, and then the slides were devel-
oped by immersion in 1.4 mmol/L 3,3′-diaminobentizine
tetrahydrochloride (Sigma Chemical Co., St. Louis, MO,
USA) in PBS.
Immunoelectron microscopy
Two percent formaldehyde PBS-fixed specimens of
normal kidney cortex were dehydrated through a se-
ries of graded ethanol, and embedded in London Resin
(LR) white resin (Polysciences, Warrington, PA, USA),
which was polymerized by ultraviolet irradiation at 4◦C
with benzoin methylether as initiator according to the
manufacturer’s instructions. Ultrathin sections were cut
and mounted on nickel grids. The grids were first in-
cubated in 5% donkey serum/PBS to prevent non-
specific binding. They were then immersed in drops
of either KYJ2 antiserum (1:250) or preimmune rab-
bit serum (1:20) diluted in 5% donkey serum for
60 minutes. After washing with PBS, the grids were im-
mersed in drops of colloidal gold (12 nm)-labeled donkey
antirabbit IgG (1:40) for 60 minutes. After washing with
deionized water, the specimens were stained with lead cit-
rate, and examined by transmission electron microscopy
(JEOL JEM-1010). For double-labeling immunoelectron
microscopy of podocin and nephrin, two different anti-
genic sites in the sections were simultaneously detected
by labeling each side of the section with a combination of
different sized gold particles as previously described [24].
Briefly, after the blocking procedure, the sections were
stained with KYJ2 antiserum (1:250) and pAb2 nephrin
(2 lg/mL), and then visualized by 12-nm or 18-nm col-
loidal gold-labeled donkey antirabbit IgG (1:40), respec-
tively.
To identify the precise intracellular localization of the
proximal C-terminus podocin mutants (R138Q, V180M,
R291W), pre-embedding immunoelectron microscopy
was performed as previously described [22, 23]. Briefly,
transfected cells were fixed with 3% formaldehyde-PBS
for 20 minutes, followed by incubation with KYJ2 anti-
serum (1:500), and developed with HRP-labeled goat an-
Table 1. List of podocin missense mutations
Effect on
Nucleotide exchange Exon # coding sequence
59C→T 1 P20L
274G→T 1 G92C
413G→A 3 R138Q
538G→A 5 V180M
871C→T 7 R291W
tirabbit antibody. After treatment with 1.4 mmol/L 3,3′-
diaminobentizine tetrahydrochloride H2O2, the glass
cover slips were treated with 1% osmium tetroxide in
0.1 mol/L phosphate buffer for 10 minutes, dehydrated
by passage through a series of graded ethanol, and em-
bedded in Epon on glass slides. Ultrathin sections were
made, stained with 0.1% lead citrate for 7 minutes, and
examined with a transmission electron microscope.
Construction of the full-length and missense mutated
podocin cDNA
A partial clone of human podocin cDNA was ampli-
fied by reverse transcription-polymerase chain reaction
(RT-PCR) from human kidney poly (A)+ RNA (Clon-
tech, Palo Alto, CA, USA) using oligonucleotide primers
(5′-GTG GTG GAC GTG GAT GAG GT-3′ and 5′-CGT
CTC CTA GCA CAT CGA TCC-3′) based on the human
podocin sequence (Genbank accession no. AJ279254),
and was subcloned with a TA cloning kit (Invitrogen,
Carlsbad, CA, USA). The digoxigenin (DIG)-labeled
probe was made using a PCR DIG probe synthesis kit
(Roche Diagnostics, Basel, Switzerland). Human kidney
cDNA library constructed from human kidney poly (A)+
RNA (Clontech) was screened with DIG-labeled probe
from the partial clone of human podocin cDNA. The full-
length clone of podocin cDNA was excised using Not I,
and was subcloned into the Not I site of pcDNA3.1 Zeo
(+) (Invitrogen). The sequencing of the human podocin
cDNA clone was done by use of a BigDye terminator cy-
cle sequencing kit (Applied Biosystems, Foster City, CA,
USA) with synthetic oligonucleotide primers using ABI
310 DNA sequencer.
Podocin missense mutations (Table 1) were created us-
ing the human podocin full-length cDNA clone as tem-
plate and a Chameleon Double-Stranded Site-Directed
Mutagenesis Kit according to the manufacturer’s proto-
col (Stratagene, La Jolla, CA, USA). After mutagenesis,
the entire mutated podocin cDNA inserts were recloned
back into the original expression vector pcDNA3.1 Zeo
(+). Finally, the entire mutated podocin cDNA inserts
were resequenced to ensure that no undesired mutations
had occurred during the mutagenesis.
Construction of the human podocalyxin cDNA
A full-length cDNA encoding the human podocalyxin
was cloned into an XbaI/BamH1-cleaved mammalian
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expression vector pcDNA3.1/Hygro (−) (Invitrogen).
Using PCR and a human podocalyxin cDNA clone [21]
as template, a PCR fragment of approximately 1600
base pairs was amplified using a 5′ upstream primer (5′-
GCTCTAGAGCCACCATGCGCTGCGCGCTGGC-
3′) with a XbaI restriction site (underlined), followed by
a Kozak sequence (double underlined) overhang tail, and
a 3′-downstream primer (5′-CGGGATCCCTAGAGG
TGTGTGTC) with a BamH1 site (underlined). The PCR
amplified cDNA fragment was gel-purified and cleaved
with the restriction enzymes (Xba1 and BamH1),
and was purified again. The cleaved PCR fragment
was cloned into the gel-purified XbaI/BamH1-cleaved
pcDNA3.1 vector. The final construct, pcDNA3.1-HPC1,
having the insert (1587 base pair long, including the
ATG start- and TAG stop codon), encoded a full-length
cDNA clone for the human podocalyxin.
Construction of the missense mutated nephrin
Two nephrin missense mutations described previously
[18], one in the fourth Ig domain (S366R), and another
one in the intracellular region part (R1140C), were used
for the cotransfection with wild-type podocin construct
as below.
Cell lines and DNA transfection
The human embryonic kidney cell line QBI293A
(Qbiogene) (HEK293 cell) was grown in Dulbecco’s
modified Eagle’s medium (D-MEM) (Life Technologies,
Gaithersburg, MD, USA) supplemented with 10% fetal
calf serum and 100 U/mL penicillin/streptomycin, in 37◦C
incubator with 5% CO2. For the generation of stably ex-
pressing wild-type podocin cell line (PDN8), HEK293
cells were plated onto 100-mm dishes and transfected
with 5 lg of plasmid DNA by using FuGeneTM6 (Roche
Diagnostics) according to the manufacturer’s protocol.
The day after transfection, cells were selected and cul-
tured in the medium containing 200 lg/mL zeocin (Cayla,
Toulouse, France).
To generate the stably expressing human podocalyxin
cell line (HEK-HPC1), HEK293 cells were transfected
with the pcDNA3.1-HPC1 construct by using FugeneTM6,
and selected and cultured in DMEM containing 200
lg/mL hygromycin (Cayla). Positive clones were tested
by immunoblotting using 3D3 antibody and cell lysates
of cultured cells (data not shown).
For the transient transfection with wild-type or mis-
sense mutated podocin cDNA, wild nephrin expressing
HEK293 cell line (NPH15 cell line) was maintained in
DMEM with 1 mg/mL geneticin (Sigma) as previously
described [20].
Immunoprecipitation
To determine the protein binding of the missense
podocin mutants to wild-type nephrin, NPH15 cell line
was transiently transfected with the cDNAs of wild-
type or each missense mutation of podocin, and then
lysed on ice with a Dounce homogenizer in lysis buffer
(10 mmol/L Tris-HCl pH 7.4, 1% Triton-X 100, 0.2%
saponin, 0.5% NP40, 150 mmol/L NaCl, 1 mmol/L sodium
vanadate, 20 mmol/L sodium fluoride, 1 mmol/L EDTA,
2 lg/mL aprotinin, 2 lg/mL leupeptin, and 100 lg/mL
phenylmethylsulfonyl fluoride). The lysates were first in-
cubated with protein A-Sepharose CL-4B (Amersham
Biosciences Co., Piscataway, NJ, USA) for one hour at
4◦C to avoid nonspecific binding of the lysates to protein
A-Sepharose beads. After washing and centrifugation,
the supernatants were incubated with peptide-purified
KYJ2 antibody overnight at 4◦C, and then again incu-
bated with protein A-Sepharose beads for one hour at
4◦C. The pellets of Sepharose beads were washed four
times with lysis buffer, and then applied for immunoblot-
ting of nephrin and podocin.
Immunoblotting
Samples of freshly isolated glomeruli, HEK293 cells
transiently transfected with wild-type or missense mu-
tated podocin constructs, and the immunoprecipitated
samples mentioned above were separated by 5% to
15% sodium dodecyl sulphate (SDS) gradient gel elec-
trophoresis under nonreducing or reducing conditions,
respectively. They were then transferred to polyvinili-
dene difluoride membranes and incubated for one hour
at room temperature with KYJ2 antiserum (1:5000) or
HRP-labeled anti-podocin antibody (0.1 lg/mL) and
pAb2 nephrin (0.2 lg/mL). The filters were then incu-
bated for 60 minutes at room temperature with or with-
out a 1:2000 diluted HRP-labeled goat antirabbit anti-
body and developed by using a Chemiluminescence kit
(Life Science Products, Boston, MA, USA) according to
the manufacturer’s instructions.
Indirect immunofluorescence and confocal microscopy
To determine the intracellular localization of wild-
type and all missense podocin mutants described above,
HEK293 cells were cultured on glass cover slips and tran-
siently transfected with the plasmid cDNAs of wild-type
or missense mutants, and further cultured for 48 hours.
The cells were washed and fixed in fixing solution (3%
formaldehyde in PBS) for 15 minutes at room tempera-
ture and permeabilized with 0.3% Triton X-100 in PBS
for 5 minutes. After incubation with blocking buffer (3%
bovine serum albumin and 5% goat serum in PBS) for
60 minutes, the cells were incubated with KYJ2 anti-
serum (1:1000) for 60 minutes at room temperature. After
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washing with PBS, the slides were incubated with Alexa
Fluor 488-conjugated goat antirabbit IgG (10 lg/mL) for
40 minutes at room temperature. For double staining of
wild-type or mutated-podocin at the proximal C-terminus
and the ER or the cis-Golgi, HEK293 cells were tran-
siently transfected with each plasmid and cultured for
48 hours with or without treatment with monensin (500
nmol/L) for the last 20 hours. Cells were fixed and per-
meabilized as above, and reacted with the KYJ2 anti-
serum and mouse monoclonal antibody against KDEL
(GRP78/94) (5 lg/mL) or GM130 (5 lg/mL), respectively.
For double staining of wild-type nephrin and wild-type
or mutated podocin, NPH15 cells were transiently trans-
fected with each podocin plasmid cDNAs. Cells were cul-
tured for 48 hours and incubated with KYJ2 antiserum
and mAb2 nephrin (1 lg/mL), followed by the incubation
with Alexa Fluor 488-conjugated goat antirabbit IgG and
Texas Red-X goat antimouse IgG (5 lg/mL).
For double labeling of podocin mutants and wild-type
podocalyxin, HEK-HPC1 cells were transiently trans-
fected with the plasmids of podocin mutants (R138Q,
R291W) and cultured for 48 hours, and prepared for im-
munofluorescence using KYJ2 antiserum and 3D3 anti-
body (1:100). The positive signals of the podocin mutants
and wild-type podocalyxin were visualized with Alexa
Fluor 488-conjugated goat antirabbit IgG and Texas Red-
X goat antimouse IgG, respectively.
For double labeling of wild-type podocin and missense
nephrin mutants, PDN8 cells were transiently transfected
with the plasmid DNAs of missense mutated nephrin
(S366R, R1140C) and cultured for 48 hours, reacted
with KYJ2 antiserum and mAb2 nephrin, and then the
positive signals of wild-type podocin and nephrin mu-
tants were visualized with Alexa Fluor 488-conjugated
goat antirabbit IgG and Texas Red-X goat antimouse
IgG, respectively. All samples were mounted in 1 mg/mL
p-phenylenediamine in PBS/glycerol (1:1) and examined
under a confocal laser scanning microscope equipped
with a Krypton/Argon laser (MRC1024, Bio-Rad; Her-
cules, CA, USA). Serial optical sections were obtained at
0.5 lm increments under the same image-capturing con-
ditions.
RESULTS
Generation and characterization of polyclonal antibody
against human podocin and colocalization of podocin
with nephrin at the slit diaphragm
To study subcellular localization of podocin in cultured
cells and human kidney sections, a rabbit polyclonal an-
tiserum was generated against a synthetic peptide cor-
responding to amino acid residues 25 to 40 of human
podocin (see Methods). A full-length cDNA clone for hu-
man podocin was obtained by screening a human kidney
cDNA library (see Methods). A mammalian expression
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Fig. 1. Characterization of the polyclonal antibody KYJ2 against hu-
man podocin. Immunoblot showing the specificity of KYJ2 antibody to
human podocin with glomerular extract and cellular lysate from a hu-
man embryonic kidney (HEK)293 cell line transfected with full-length
human podocin cDNA construct (PDN8). Fifty lg protein of lysates
from isolated human glomeruli and PDN8 cells were separated on 5%
to 15% gradient gels under reducing or nonreducing condition, and
immunoblotted with KYJ2 antiserum (1:5000). Under reducing condi-
tion, a specific immunoband of 49 kD corresponding to the calculated
molecular mass of human podocin was detected (A). Under nonreduc-
ing conditions, in addition to the 49 kD band, multiple protein forms of
98 and 147 kD corresponding to dimer and trimer were also recognized
by the antiserum (B). Preimmune rabbit serum as negative control did
not show any reactivity with protein samples from isolated glomeruli
or PDN8 cells (C).
vector containing the full-length cDNA clone was used to
generate stable HEK293 cell line expressing the human
podocin.
The specificity of polyclonal antibody (KYJ2) was
first tested by immunoblotting using samples of iso-
lated human glomeruli and PDN8 cell line. As shown in
Figure 1A, this antibody detected a specific protein band
with a molecular mass of 49 kD in both samples un-
der reducing conditions. This molecular migration of hu-
man podocin is consistent with that described by Roselli
et al [12]. Higher molecular masses of 98 kD and 147 kD
were also seen in the same extracts of both samples un-
der nonreducing conditions (Fig.1B), indicating that un-
der nonreducing condition podocin molecules may form
dimers and oligomers both in vivo and in cell culture. Sim-
ilar observations have been reported for mouse podocin
[13]. No positive signals were observed in these samples
using preimmune rabbit serum, showing the specificity of
the antiserum (Fig. 1C).
We next tested the cellular and subcellular localization
of podocin in the human kidney sections. As shown in
Figure 2A and B, immunoperoxidase staining of hu-
man normal kidney with KYJ2 antiserum showed a
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Fig. 2. Immunohistochemistry and immunoelectron microscopy of
normal human kidney sections using the antiserum KYJ2. Frozen
sections of normal human kidney cortex were immunostained with
KYJ2 antiserum or preimmune rabbit serum (1:500) as control. The
glomerular-specific pattern of the KYJ2 antiserum is shown in low
magnification (A). At higher magnification (B), immunostaining of the
glomerular capillary loops with a glomerular basement membrane–like
pattern is visible. No positive immunoreactivity was seen in the adjacent
specimens immunostained with preimmune serum (C and D). Bars
indicate 100 lm. Immunogold electron microscopy showing the subcel-
lular localization of podocin in the human glomerulus (E). Immunogold
labels are seen at the base of podocyte foot processes, along with the
glomerular basement membrane (arrowheads). In oblique section
(F), parallel to the podocyte slit diaphragm, immunogold labels show
localization of podocin molecules at the slit diaphragm areas between
the adjacent foot processes (arrowheads). Lack of immunoreactivity
is shown in kidney sections incubated with the preimmune serum
(G). Colocalization of podocin with nephrin in the human glomeru-
lus by double-labeling immunoelectron microscopy (H). One side of an
glomerular-specific localization of podocin. On the
other hand, preimmune serum showed no reactivity
(Fig. 2C and D). Specific localization of podocin at the
SD of podocyte foot processes was also shown by post-
embedding immunoelectron microscopy (Fig. 2E and F).
Furthermore, double-labeled immunoelectron mi-
croscopy using KYJ2 and antibody against the intracel-
lular part of nephrin clearly showed colocalization of
podocin and nephrin at the SD (Fig. 2H).
Subcellular localization of wild-type and missense mu-
tated podocin in transfected cells
To study the effect of missense mutations in podocin,
five different disease-causing missense mutations found
in SRN patients (Table 1) with severe proteinuria were
introduced into the full-length construct for human
podocin. Two of these missense mutations (P20L and
G92C) were located at the N-terminus part of the
molecule, while the other three (R138Q, V180M, and
R291W) were located at the C-terminus. These cDNA
constructs were used to transfect wild-type HEK293 cells
for transient expression. To compare the molecular mass
of podocin missense mutants expressed in HEK293 cells
with that of wild-type podocin, cellular lysates transiently
transfected with each podocin constructs were examined
by immunoblotting. The molecular mass of all podocin
mutants was detected to be 49 kD, similar to that of
cells expressing the wild-type construct and glomeru-
lar extract (Fig. 3A). To further determine the localiza-
tion of wild-type and mutated podocin in HEK293 cells,
we performed immunofluorescence staining followed by
confocal microscopy with transiently transfected cells.
As shown in Figure 3B, wild-type podocin was clearly
observed at the plasma membrane, including the tip
of cellular processes, together with small dotted pat-
tern throughout the cytoplasm. In contrast to this, there
were clear differences of subcellular localization among
podocin missense mutants. The localization of missense
mutants at the proximal N-terminus (P20L, G92C) were
shown to be basically the same as that of wild-type,
although its plasma membrane expression tended to
decrease compared to wild-type. On the other hand,
subcellular localization of the mutants at the proximal
C-terminus part (R138Q, V180M, R291W) was found to
be considerably different from that of wild-type. While
R138Q and R291W mutants showed a more similar
diffuse-reticular staining pattern in the cytoplasm, the
ultrathin section was stained with anti-podocin KYJ2 antiserum, and
the other side with purified polyclonal antinephrin antibody against the
intracellular domain. Podocin and nephrin molecules are colocalized as
12-nm and 18-nm gold particles, respectively (arrowheads). Size bars of
200 nm are indicated.
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Fig. 3. Molecular migration and subcellular localization of wild-type
and missense mutated podocin. Immunoblot analysis of protein ex-
tract isolated from human glomeruli and human embryonic kidney
(HEK)293 cells transiently transfected with cDNA constructs encod-
ing a wild-type or five different podocin missense mutants (P20L, G92C,
R138Q, V180M, and R291W) (A). Lysates were separated on a 5% to
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gradient gel and immunoblotted with the KYJ2 antiserum.
An immunoband of 49 kD was seen in all samples. Immunolocaliza-
tion of wild-type and missense mutated podocin in transiently trans-
fected HEK293 cells (B). Cells were cultured and immunostained with
KYJ2 antiserum (1:500). Similar to wild-type podocin, missense mu-
tants (P20L and G92C) located at the N-terminus of the human podocin
molecule showed plasma membrane and cell process localization. In
contrast, podocin molecules (R138Q, V180M, and R291W) that mu-
tated at the C-terminus were retained within the cell and did not show
plasma membrane localization. Bars indicate 50 lm.
V180M podocin mutant showed vesicular pattern stain-
ing with irregular shape and sizes. What was even more
noticeable for V180M mutant was that the staining pat-
tern for this mutant was time-dependent, changing from
smaller and dispersed vesicular staining at 24 hours post-
transfection (not shown) to larger irregular vesicular
staining with aggregated inclusion bodies in the cyto-
plasm and some very weak staining at the plasma mem-
brane when stained 48 hours post-transfection (Fig. 3B).
To further study the subcellular localization of these
mutants, we performed double-immunostaining using an
ER-specific monoclonal antibody against the peptide se-
quence KDEL, which is present at the C-terminus of
all ER-resident proteins, and a Golgi-specific antibody
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Fig. 4. Subcelluar localization of the C-terminal missense mutated
podocin. Double immunofluorescence of R138Q, V180M, and R291W
podocin mutants and the endoplasmic reticulum (ER) marker, KDEL
(GRP78/94) (A). R138Q mutant was clearly retained in the ER, whereas
R291W was partly localized in this compartment. Colocalization with
the Golgi marker, GM130, in cells transiently transfected with each
plasmid without monensin treatment. Prominent Golgi localization was
seen only with wild-type podocin (B). Colocalization with the Golgi
marker, GM130, 20 hours post monensin-treatment (C). V180M and
R291W podocin mutants and the wild-type podocin were clearly re-
tained in the Golgi, while subcellular localization of R138Q was not
changed by monensin treatment.
against the Golgi-resident protein GM130. As shown
in Figure 4A, and also reported by others [25–27], the
R138Q mutant was clearly localized to the ER compart-
ment. Similar to the R138Q mutant, R291W podocin
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Fig. 5. Pre-embedding immunoelectron microscopy of podocin mu-
tants. Human embryonic kidney (HEK)293 cells expressing plasmid
constructs encoding the wild-type and C-terminus podocin mutants
were fixed and processed for immunoelectron microscopy by using
antihuman podocin–specific antibody as described in the text. Wild-
type podocin is predominantly accumulated in the plasma membrane
(arrows) (A). R138Q mutant shows perinuclear endoplasmic reticu-
lum (ER) localization in addition to specific localization on the ER-
associated tubular structures (arrows) (B). Plasma membrane local-
ization was not observed (arrowheads). V180M mutant shows inclu-
sion body staining within vesicular structures (arrows) (C). Staining
for R291W mutant shows both vesicular localization (arrows) (D), and
ER-associated tubular structures (arrowheads). Bar indicates 1 lm.
mutant also showed localization in the ER (Fig. 4A). As
it was expected, wild-type podocin was mostly localized
at the plasma membrane, but it also showed colocaliza-
tion with the ER marker and a distinct localization in
the Golgi, indicating its normal traffic through ER and
Golgi to the plasma membrane (Fig. 4A and B). In con-
trast to the wild-type, this clear localization in the Golgi
was not observed for the C-terminus podocin mutants
(Fig. 4B). When cells were further treated with the Golgi-
perturbing agent monensin [28], both V180M and R291W
mutants, as well as the wild-type podocin were clearly
colocalized with the Golgi marker, suggesting that their
traffic was perturbed in the Golgi (Fig. 4C). In contrast,
the localization of R138Q was not altered by monensin
treatment (Fig. 4C), indicating that this mutant was al-
ready retained in the ER, as shown in Figure 4A.
We next performed pre-embedding immunoelectron
microscopy of the cells to identify the precise subcellular
localization of each podocin mutants. As it was expected,
the wild-type podocin was predominantly localized at the
plasma membrane (Fig. 5A), whereas the R138Q mutant
clearly showed a strong perinuclear localization (Fig. 5B),
consistent with its retention in the ER as shown in
Figure 4A. V180M mutant showed an inclusion body
staining pattern within irregular vesicular structures out-
side of ER and Golgi compartments (Fig. 5C). And finally,
cells expressing the R291W mutant appeared to accumu-
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Fig. 6. The proximal C-terminus podocin missense mutants specifi-
cally interfere with wild-type nephrin trafficking. Double-labeling im-
munofluorescence of wild-type nephrin and wild-type or missense mu-
tated podocin (A). Nephrin-expressing cell line (NPH15) was tran-
siently transfected with wild-type or each missense mutated podocin
cDNAs, followed by immunostaining with KYJ2 antibody and an-
tinephrin monoclonal antibody. Wild-type nephrin colocalizes with
C-terminal mutated podocin mutants R138Q, V180M, and R291W.
Double-labeling immunofluorescence of podocin mutants, R138Q and
V180M, and podocalyxin (B). Human podocalyxin-expressing cell line
(HEK-HPC1) was transiently transfected with R138Q and V180M cD-
NAs, followed by immunostained with KYJ2 antibody and 3D3 mono-
clonal antibody. The proper localization of podocalyxin on the plasma
membrane was not affected by coexpression of the podocin mutants.
Double-labeling immunofluorescence of nephrin missense mutants and
wild-type podocin (C). PDN8 cell line was transiently transfected with
nephrin mutants, S366R and R1140C, followed by immunostaining with
KYJ2 antibody and antinephrin monoclonal antibody. The subcellular
localization of wild-type podocin was not altered by nephrin mutants,
S366R and R1140C. Bar length is 50 lm.
late the mutant protein both in small vesicular structures
outside the ER and in the tubular-like structure within
the ER.
Podocin missense mutants interfere with the proper
traffic of wild-type nephrin
It has been reported that podocin interacts with intra-
cellular nephrin, and both molecules can be isolated from
specialized lipid rafts at the SD structure [13]. There-
fore, we next studied whether these podocin missense
mutants may affect the proper protein trafficking of wild-
type nephrin. To this end, a stable transfected cell line ex-
pressing wild-type nephrin, NPH15, was transfected with
cDNA constructs encoding each missense podocin mu-
tants, and then were studied using double-labeling im-
munostaining. As shown in Figure 6A, wild-type podocin
and nephrin were clearly colocalized predominantly at
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the plasma membrane; however, as indicated before, in-
tracellular staining of both proteins were also seen in the
ER and Golgi-like pattern. Expression of the N-terminal
mutants, P20L and G92C, in the NPH15 cells did not alter
the plasma membrane localization of wild-type nephrin,
indicating that these missense mutations had no effect on
nephrin localization (Fig. 6A). In contrast, and interest-
ingly, when C-terminus podocin mutants were expressed
in NPH15 cells, the normal membrane localization of
wild-type nephrin was dramatically altered. In cells ex-
pressing the R138Q mutant, previously shown to be
retained in the ER, wild-type nephrin was also found
abundantly in the ER, and was completely absent from
the plasma membrane (Fig. 6A). Normal localization of
wild-type nephrin was also altered in cells expressing
V180M and R291W mutants, in which nephrin was absent
at the plasma membrane, but instead colocalized with the
mutant proteins in the same intracellular compartments.
To find out whether this colocalization of wild-type
nephrin and podocin mutants was not due to ER over-
loading in transient expression system, we chose to test
the localization of yet another podocyte cell membrane
protein, podocalyxin. Podocalyxin is a transmembrane
sialoprotein known for its localization on the podocyte
plasma membrane, but not at the SD region. Stable
HEK293 cells were established to express a full-length
cDNA clone encoding human podocalyxin [21]. Double-
staining of such cells showed that the plasma membrane
localization of podocalyxin was altered neither by expres-
sion of R138Q nor V180M podocin mutants (Fig. 6B). It
was concluded that the interruption of wild-type nephrin
trafficking was due to the interaction of nephrin and mis-
localized podocin mutants.
We finally extended this finding to ask whether
missense mutated nephrin molecules may affect the
protein trafficking of wild-type podocin. We have pre-
viously shown that a number of missense mutations in
the nephrin molecule are retained in the ER and do not
appear on the plasma membrane [18]. Two such nephrin
missense mutants were selected; one for its ER localiza-
tion (S366R, located in the fourth extracellular Ig-like
domain of nephrin), and the other one with no alteration
in the trafficking (R1140C, located in the intracellular
C-terminus). The PDN8 cells, expressing the wild-type
podocin, were cotransfected with plasmid constructs en-
coding the nephrin mutations. The transport and localiza-
tion of wild-type podocin and mutated nephrin molecules
were followed by double immunostaining. As shown in
Figure 6C, coexpression of nephrin mutants did not affect
the localization of wild-type podocin.
Finally, we performed a coimmunoprecipitation study
to determine whether the direct protein interaction
between mutated podocin and wild-type nephrin under-
lies this defect of nephrin trafficking. The result demon-
strated that nephrin was apparently pulled down by
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Fig. 7. Pull-down experiment showing protein interactions between
wild-type nephrin and the proximal C-terminal podocin mutants. Pro-
tein samples from the cells transiently transfected with the cDNAs
of wild-type, an N-terminus mutated podocin (P20L), and the proxi-
mal C-terminus missense podocin mutants were coimmunoprecipitated
with peptide-purified KYJ2 antibody, followed by immunoblotting with
HRP-labeled KYJ2 antibody and antihuman nephrin antibody. NPH15
cells (nephrin-expressing cell line) were used as a negative control.
anti-podocin antibody in the samples from nephrin-
expressing cells transfected with all the proximal C-
terminal mutants of podocin, as well as wild-type and
N-terminal mutant P20L, indicating a tight association
between nephrin and podocin molecules (Fig. 7).
DISCUSSION
Defects in intracellular protein trafficking, resulting in
the accumulation and aggregation of misfolded proteins
in the cells, are a common causative factor in develop-
ment of many human diseases [29, 30]. In most cases, this
alteration in protein trafficking occurs due to missense
mutations, leading to secondary protein structures and
misfolding of the protein as the consequence.
The ER is a very specialized subcellular compart-
ment, providing the cell a selective environment for
complex protein folding and assembly [31]. Protein
complex formation and assembly of the newly formed
polypeptides are stringently orchestrated by the pro-
cess of conformation-dependent molecular chaperones,
also called quality control system [32]. In the ER, sev-
eral cotranslational (such as signal-peptide cleavage) and
post-translational modifications (such as glycosylation
and disulphide bond formation) take place to ensure
that newly synthesized secreted or membrane-integrated
proteins are correctly transported to their final destina-
tions. Along with this the presence of molecular chaper-
ones, such as the glucose-regulated protein 78 (GRP78)
[33], the glucose-regulated protein 94 (GRP94) [34],
lectin-like chaperones (calnexin, calreticulin) [35, 36],
and disulphide-isomerase [37] are critical for proper pro-
tein folding and assembly.
The aim of the present study was to investigate whether
and how the disease-causing missense mutations in the
NPHS2 gene are involved in the pathomechanism of
the proteinuria in patients carrying such mutations. In
order to address this question, we introduced five mis-
sense mutations into a full-length cDNA construct en-
coding the wild-type human podocin, and studied the
localization of the mutant proteins in transfected cells.
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As a tool, we further generated a polyclonal antibody
against a synthetic peptide corresponding to amino acid
residues 25 to 40 in the human podocin. The specificity
of this polyclonal antibody was demonstrated by Western
blot analysis on protein extracts from human kidney and
transfected cells expressing the wild-type podocin con-
struct (Fig. 1). As expected, immunohistochemistry and
electron microscopy studies on human kidney sections
demonstrated that polyclonal KYJ2 antibody localized
its antigen podocin specifically to the podocyte SD re-
gion in the vicinity of nephrin (Fig. 2). Transfection stud-
ies using the HEK293 cells revealed that in contrast to
the wild-type podocin, several podocin mutants were not
targeted to the plasma membrane. Similar results have
also been recently reported by others [25–27]; however,
some discrepancies remain to be clarified. In their re-
port, Roselli et al investigated subcellular localization
of a number of disease-causing podocin mutants using
HEK293 cells, in which V180M mutant was observed in
the plasma membrane. Our extensive studies on this mu-
tant showed that only a minor fraction of the mutant ap-
peared on the plasma membrane, and the majority of
the mutant remains as intracellular inclusion bodies in a
time-dependent manner. Since with monensin treatment
the inclusion body staining pattern of this mutant was
abolished and the mutant was retained in the Golgi, it
is most likely that the traffic of V180M podocin mutant
is altered in the endosomes or lysosomes after exiting
from the Golgi, and not degraded by the cytoplasmic-
ubiquitin-proteasome pathway such as aggresomes [38].
Perhaps higher expression levels in our transiently trans-
fected studies compared to cell lines with stable expres-
sion used by Roselli et al may underlie the discrepancy
in localization of this particular mutant. In fact, the dif-
ference in expression levels may explain why the other
C-terminus mutant (R238S) also reached to the plasma
membrane [27], while in our studies the C-terminus mu-
tants did not reach to the plasma membrane. For the fate
of R291W mutant, our data are in good agreement with
that reported by Roselli et al, suggesting that this mu-
tant was retained in the late endosomes [27]. However,
as shown by our immunoelectron microscopy studies, we
also concluded that this mutant, at least partially, retains
the ER localization (Fig. 5). As the protein quality con-
trol by the chaperones occurs at different stages through
ER and Golgi, and artificial overexpression of mutant
proteins in cells may cause overloading of this system, it
is difficult to unequivocally determine the fate of some
missense mutations that may not cause an immediate ag-
gregation or misfolding of the mutated polypeptide.
Although many missense mutations are known to inter-
fere with trafficking and proper subcellular destinations
[29, 30], it is little known what amino acid substitutions
are generally responsible for this defect of intracellular
trafficking. It has been shown that several ER resident
motifs, such as KDEL [39] and dilysine [40], confer ER
localization of membrane proteins; however, the amino
acid substitutions of R138Q and R291W do not contain
these motifs. Many misfolded integral proteins inappro-
priately expose hydrophobic surfaces that are normally
buried inside the protein or at the interface with other
subunits [41]. Perhaps the substitution of the arginine
residue in both R138Q and R291W mutants, in which the
positively charged arginine residue is replaced with an un-
charged glutamine residue or a bulky aromatic side chain
such as tryptophan, leads to interruption of an important
intra- or intermolecular interaction within or between the
mutant podocin molecules. In fact, as shown by Schwarz
et al [13], oligomerization of podocin molecules and its
association with other SD components such as nephrin
and CD2AP in the lipid rafts isolate from glomerulus
and transfected cells, suggesting that intermolecular in-
teraction between podocin molecules may be essential
for its localization and function. In this regard, we found
that normal trafficking of wild-type nephrin was dramati-
cally affected in cells coexpressing nephrin together with
podocin mutants carrying mutations in the proximal C-
terminal part. Our pull-down study clearly demonstrated
that such mutations did not affect the intermolecular in-
teraction between nephrin and the podocin mutants, as
nephrin could be pulled down from the cellular lysates
(Fig. 7). Colocalizaton of nephrin in cells expressing these
podocin mutants, rather, points to the possibility that af-
ter binding to podocin mutants, nephrin molecules are
also recruited to other cellular compartments than the
plasma membrane.
CONCLUSION
An important unresolved issue, however, is to find
out whether there is a correlation between NPHS1 and
NPHS2 mutations (genotype) and the severity or the on-
set of proteinuria (phenotype) in patients with hered-
itary nephrotic syndrome. Koziell et al have recently
reported on such potential genotype/phenotype correla-
tions between these two genes in patients diagnosed as
CNF, SRN, or congenital FSGS [42]. For example, coex-
istence of both NPHS1 and NPHS2 mutations was found
in all tested patients with congenital FSGS, suggesting
a potential functional and corroborative effect between
these two genes. Two out of five typically severe CNF pa-
tients were also found to lack mutations in NPHS1 gene;
however, the patients carry homozygous mutations in the
NPHS2 gene [42]. Taken together with our present data,
one may speculate that some mutations in NPHS2 gene
may not necessarily lead to nephrotic syndrome charac-
terized by SRN phenotype, but instead, the disease may
be manifested as severe CNF because the fate of wild-
type nephrin may also be affected in such patients.
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